Lv7
5000 积分 2022-03-17 加入
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
2天前
已完结
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy
1个月前
已完结
Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
2个月前
已完结
Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China
2个月前
已完结
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
2个月前
已完结
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
3个月前
已完结
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
4个月前
已关闭
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
4个月前
已完结
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
4个月前
已完结
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
4个月前
已完结
皖公网安备34019202002308
